Efficacy and safety of azelastine 0.15% nasal spray administered once daily in subjects with seasonal allergic rhinitis

Allergy and Asthma Proceedings

Volumn 30, Issue 5, 2009, Pages 512-518

  Van Bavel, Julius ^a   Howland, William C ^a   Amar, N J ^b   Wheeler, William ^c   Sacks, Harry ^c  

^a Allergy and Asthma Associates   (United States)

^b Allergy and Asthma Research Institute   (United States)

^c Meda Pharmaceuticals Inc   (United States)

Author keywords

Allergic rhinitis; Antihistamine; Azelastine; Clinical trial; Compliance; Efficacy; Nasal congestion; Nasal spray; Runny nose; Safety

Indexed keywords

ASTEPRO; AZELASTINE; PLACEBO; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BITTER TASTE; BRONCHITIS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; FEVER; HAY FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSAL BLEEDING; NASAL PRURITUS; NAUSEA; NOSE CONGESTION; NOSE DISEASE; NOSE IRRITATION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RHINORRHEA; SCHOOL CHILD; SCORING SYSTEM; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINUSITIS; SNEEZING; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-ALLERGIC AGENTS; CHILD; DOUBLE-BLIND METHOD; FEMALE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; MALE; MIDDLE AGED; PHTHALAZINES; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 73249144817     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2009.30.3284     Document Type: Article

References (31)

1. Rosenwasser LJ. Treatment of allergic rhinitis. Am J Med 113: 17S-24S, 2002.
2. Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc 28:3-9, 2007.
3. Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: An updated practice parameter. J Allergy Clin Immunol 122:S1-S84, 2008.
4. American Academy of Allergy Asthma and Immunology. Allergy statistics. Available online at www.aaaai.org/media/resources/media-kit/allergy-statistics. stm; accessed May 19, 2009.
5. Nathan RA, Meltzer EO, Derebery J, et al. The prevalence of nasal symptoms attributed to allergies in the United States: Findings from the burden of rhinitis in an America survey. Allergy Asthma Proc 29:600-608, 2008.
6. Soni A. Allergic rhinitis: Trends in use and expenditures, 2000 to 2005. Statistical Brief 204, Agency for Healthcare Research and Quality, Rockville, MD, 2008.
7. Zechel HJ, Brock N, Lenke D, et al. Pharmacological and toxicological properties of azelastine, a novel antiallergic agent. Arzneimittelforsch 31:1184-1193, 1981.
8. Chand N, Pillar J, Nolan K, et al. Inhibition of allergic and nonallergic leukotriene C4 formation and histamine secretion by azelastine: Implication for its mechanism of action. Int Arch Allergy Appl Immunol 90:67-70, 1989.
9. Hamasaki Y, Shafigeh M, Yamamoto S, et al. Inhibition of leukotriene synthesis by azelastine. Ann Allergy Asthma Immunol 76:469-475, 1996.
10. Shin MH, Baroody F, Proud D, et al. The effect of azelastine on the early allergic response. Clin Exp Allergy 22:289-295, 1992.
11. Shinoda M, Watanabe N, Suko T, et al. Effects of anti-allergic drugs on substance P (SP) and vasoactive intestinal peptide (VIP) in nasal secretions. Am J Rhinol 11:237-241, 1997.
12. Nieber K, Baumgarten C, Rathsack R, et al. Effect of azelastine on substance P content in bronchoalveolar and nasal lavage fluids of patients with allergic asthma. Clin Exp Allergy 23:69-71, 1993.
13. Ito H, Nakamura Y, Takagi S, et al. Effects of azelastine on the level of serum interleukin-4 and soluble CD23 antigen in the treatment of nasal allergy. Arzneimittelforsch 48:1143-1147, 1998.
14. Ciprandi G, Pronzato C, Passalacqua G, et al. Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: An antiallergic activity. J Allergy Clin Immunol 98:1088-1096, 1996.
15. Juniper EF, Thompson AK, Ferrie PJ, et al. Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. J Allergy Clin Immunol 104:364-369, 1999.
16. International Federation of Pharmaceutical Manufacturers and Associations. Medical Dictionary for Regulatory Activities. Available online at www.meddramsso.com/MSSOWeb/index. htm; last accessed August 2009.
17. Midoro-Horiuti T, Goldblum RM, Kurosky A, et al. Isolation and characterization of the mountain cedar (Juniperus ashei) pollen major allergen, Jun a 1. J Allergy Clin Immunol 104:608-612, 1999.
18. Midoro-Horiuti T, Goldblum RM, Kurosky A, et al. Molecular cloning of the mountain cedar (Juniperus ashei) pollen major allergen, Jun a 1. J Allergy Clin Immunol 104:613-617, 1999.
19. Andre C, Dumur JP, Hrabina M, et al. Juniperus ashei: The gold standard of the Cuppressaceae. Allerg Immunol (Paris) 32:104-106, 2000.
20. Ratner PH, Findlay SR, Hampel F Jr, et al. A double-blind, controlled trial to assess the safety and efficacy of azelastine nasal spray in seasonal allergic rhinitis. J Allergy Clin Immunol 94:818-825, 1994.
21. Storms WW, Pearlman DS, Chervinsky P, et al. Effectiveness of azelastine nasal solution in seasonal allergic rhinitis. Ear, Nose, Throat J 73:382-386, 1994.
22. Berger WE, and White MV. Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine. Ann Allergy Asthma Immunol 91:205-211, 2003.
23. Corren J, Storms W, Bernstein J, et al. Effectiveness of azelastine nasal spray compared with oral cetirizine in patients with seasonal allergic rhinitis. Clin Ther 27:543-553, 2005.
24. Berger W, Hampel F Jr, Bernstein J, et al. Impact of azelastine nasal spray on symptoms and quality of life compared with cetirizine oral tablets in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 97:375-381, 2006.
25. Bernstein JA, Prenner B, Ferguson BJ, et al. Double-blind, placebocontrolled trial of reformulated azelastine nasal spray in patients with seasonal allergic rhinitis. Am J Rhinol Allergy 23:512-517, 2009.
26. Meda Pharmaceuticals, Inc. Astepro (azelastine hydrochloride) nasal spray prescribing information. Somerset, NJ; 2008.
27. LaForce CF, Corren J, Wheeler WJ, et al. Efficacy of azelastine nasal spray in seasonal allergic rhinitis patients who remain symptomatic after treatment with fexofenadine. Ann Allergy Asthma Immunol 93:154-159, 2004.
28. Farmer KC, Jacobs EW, and Phillips CR. Long-term patient compliance with prescribed regimens of calcium channel blockers. Clin Ther 16:316-326, 1994.
29. Kardas P. Compliance, clinical outcome, and quality of life of patients with stable angina pectoris receiving once-daily betaxolol versus twice daily metoprolol: A randomized controlled trial. Vasc Health Risk Manag 3:235-242, 2007.
30. Kardas P. Comparison of patient compliance with once-daily and twice-daily antibiotic regimens in respiratory tract infections: Results of a randomized trial. J Antimicrob Chemother 59:531-536, 2007.
31. Viciana P, Rubio R, Ribera E, et al. Longitudinal study on adherence, treatment satisfaction, and effectiveness of once-daily versus twice-daily antiretroviral therapy in a Spanish cohort of HIV-infected patients (CUVA study). Enferm Infecc Microbiol Clin 26:127-134, 2008.